Cancer News and Research

Latest Cancer News and Research

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.

16 May 2012

Mass. Eye and Ear announces recipients of 2012 Curing Kids Fund grants

The Mass. Eye and Ear Curing Kids fund has awarded grants for research projects that aim to help the brain locate sound, identify genes that cause congenital blindness, cure deafness through hair cell regeneration, and improve treatment for childhood eye cancer.

16 May 2012

Positive data from Theraclone Sciences’ TCN-032 Phase 1 trial on influenza A infection

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections.

16 May 2012

Link between dietary supplements and increased risk of cancer

Beta-carotene, selenium and folic acid - taken up to three times their recommended daily allowance, these supplements are probably harmless. But taken at much higher levels as some supplement manufacturers suggest, these three supplements have now been proven to increase the risk of developing a host of cancers.

16 May 2012

Novelos completes I-131-CLR1404 Phase 1b trial on advanced solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the first cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.

16 May 2012

Cyclophosphamide drug makes the bone marrow more tumor-friendly

Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily.

15 May 2012

Lab21’s HCV drug resistance genotyping receives new patents in the U.S., Europe

Lab21 Limited, the Cambridge, UK-based specialist in personalised medicine has secured new patents in Europe and the USA relating to Hepatitis C (HCV) drug resistance as it continues to expand its intellectual property portfolio in infectious disease testing.

15 May 2012

New Liquid ready-to-use Tumour Marker Control available now from Randox

The new Randox Acusera multi-analyte Liquid Tumour Marker Control covers a total of 15 commonly tested and esoteric cancer antigens and tumour markers. The addition of assayed target values enables laboratories to effectively monitor both accuracy and precision.

From Randox Laboratories Ltd. 15 May 2012

Many men do not protect their skin from sun exposure

As everyone knows, growing older brings an increased number of health concerns. In fact, dermatologists warn that men older than 50 have an increased risk of developing melanoma - the deadliest form of skin cancer.

15 May 2012

First study to track movement of individuals with dementia until death

A new study from the Regenstrief Institute and Indiana University has found that, at time of death, individuals with dementia are more likely to be living at home than in a nursing home. This contradicts the commonly held view that most individuals with dementia in the United States eventually move to nursing homes and die there.

15 May 2012

Persistent Systems, TGen collaborate on Bio4D software program

Persistent Systems, the leader in outsourced software product development (OPD) services, and the Translational Genomics Research Institute (TGen) today announced that they are developing a high-quality biospecimen management system called Bio4D.

15 May 2012

BI-RADS useful in predicting malignant breast lesions detected with MRI

A large, multicenter study found that the Breast Imaging and Reporting Data Systems (BI-RADS) terminology used by radiologists to classify breast imaging results is useful in predicting malignancy in breast lesions detected with MRI. Results of the study are published online in the journal Radiology.

15 May 2012

Significant breakthrough in understanding the cause of bile duct cancer

A team of international scientists has made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes frequently mutated in bile duct cancers, researchers are paving the way for better understanding of how bile duct cancers develop. Their discovery is published online in Nature Genetics.

15 May 2012

Study identifies biomarkers that can predict recurrence of prostate cancer

Alterations to the "on-off" switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches, a Mayo Clinic study has found.

15 May 2012

Paediatric brain tumours preserve specific characteristics of normal cells from which they originate

Paediatric brain tumours preserve specific characteristics of the normal cells from which they originate - a previously unknown circumstance with ramifications for how tumour cells respond to treatment.

15 May 2012

Genetic test can accurately predict spread of eye cancer

Researchers at Washington University School of Medicine in St. Louis have developed a genetic test that can accurately predict whether the most common form of eye cancer will spread to other parts of the body, particularly the liver.

15 May 2012

Ono, Scil Proteins partner to discover and develop new Affilin therapeutics

Scil Proteins GmbH, a private biotech company specializing in the research, development and production of recombinant proteins, today announced that it has signed a collaboration agreement with Ono Pharmaceutical Co., Ltd., for the joint discovery and development of new Affilin therapeutics to treat various diseases.

15 May 2012

Scientists discover curious twist in chalcone-isomerase

A curious twist in a family of plant proteins called chalcone-isomerase recently was discovered by Salk Institute for Biological Studies scientist Joseph Noel and colleagues at Iowa State University led by Eve Wurtele.

15 May 2012

Viewpoints: Approving drugs quickly; Berwick: In health care, cheaper can mean better; Health costs 'persistent' concern

For about 20 years, the Food and Drug Administration (FDA) has charged pharmaceutical companies "user fees" for reviewing drug-approval applications. The revenue allows the FDA to hire more evaluators, which allows useful drugs to reach patients faster. Now the Prescription Drug User Fee Act needs reauthorization, as it does every five years. Legislators should not dillydally.

15 May 2012

Many young adults not aware of tanning bed dangers

Despite the fact that young adults are generally in constant communication via social media and texting, a new survey finds many in this age group are not getting the message that there is no such thing as a safe tan.

15 May 2012